BML Capital Management, LLC — 13F Holdings & Portfolio

CIK 1616824 · latest 13F-HR filed 2026-05-06

BML Capital Management, LLC manages $155.8M in 13F-reported U.S. long-equity assets across 16 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ACRS (34.31%), AVIR (24.38%), ORMP (6.91%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 3 new positions, exited 1, added to 7, and trimmed 3.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$155.8M

Long-equity book

Holdings

16

Distinct positions

Period

2026-03-31

Filed 2026-05-06

Q/Q Activity

+3 / −1 / ↑7 / ↓3

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • ATEA PHARMACEUTICALS INC$11.2M +42.0%
  • ACLARIS THERAPEUTICS INC$10.5M +24.6%
  • OUTSET MED INC$5.3M +262.5%
  • ORAMED PHARMACEUTICALS INC$1.7M +19.3%
  • TARGET CORP$879.4K +24.0%
Show all 7

Top Trims

  • INSTIL BIO INC-$1.8M -25.1%
  • IMAGENEBIO INC-$217.8K -17.8%
  • CONNECT BIOPHARMA HLDGS LTD-$81.8K -7.1%
Show all 3

New Positions

  • TILLYS INC$8.7M
  • KRAFT HEINZ CO$2.8M
  • JANUX THERAPEUTICS INC$2.2M
Show all 3

Exited Positions

  • LISATA THERAPEUTICS INC$136.4K
Show all 1
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 ACLARIS THERAPEUTICS INC ACRS 00461U105 $53.4M 34.31% 14,250,000 SH
2 ATEA PHARMACEUTICALS INC AVIR 04683R106 $38.0M 24.38% 7,058,657 SH
3 ORAMED PHARMACEUTICALS INC ORMP 68403P203 $10.8M 6.91% 3,167,231 SH
4 TILLYS INC TLYS 886885102 $8.7M 5.59% 2,150,000 SH
5 OUTSET MED INC OM 690145206 $7.3M 4.69% 1,902,201 SH
6 PMV PHARMACEUTICALS INC PMVP 69353Y103 $6.6M 4.24% 5,320,000 SH
7 CARMAX INC KMX 143130102 $6.4M 4.14% 155,000 SH
8 KEZAR LIFE SCIENCES INC KZR 49372L209 $5.3M 3.43% 720,787 SH
9 INSTIL BIO INC TIL 45783C200 $5.3M 3.42% 645,600 SH
10 TARGET CORP TGT 87612E106 $4.5M 2.92% 37,500 SH
11 KRAFT HEINZ CO KHC 500754106 $2.8M 1.80% 125,000 SH
12 JANUX THERAPEUTICS INC JANX 47103J105 $2.2M 1.38% 154,961 SH
13 PLIANT THERAPEUTICS INC PLRX 729139105 $1.9M 1.25% 1,546,137 SH
14 CONNECT BIOPHARMA HLDGS LTD CNTB G23549101 $1.1M 0.69% 408,887 SH
15 IMAGENEBIO INC IMA 45175G207 $1.0M 0.64% 200,730 SH
16 WALMART INC Put WMT 931142103 $329.1K 0.21% 335 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-06 $155.8M 16 0001754960-26-000359
2025-12-31 2026-02-03 $115.7M 16 0001754960-26-000146